


**Supplementary Figure 1. PD-L1 expression in the TC-1 syngeneic tumor increased with PDS0101 treatment.** TC-1 tumor bearing female C57BL/6J mice were treated with PBS control (100  $\mu$ l s.c) or PDS0101 (s.c., 2 weekly doses starting on day 7). Tumors were harvested and processed using the Mouse Tumor Dissociation kit (Miltenyi). Cells were stained with CD45 (clone# 30-F11) and PDL1 (clone # 10F.9G2) antibodies, and run on an Attune 4-laser flow cytometer. Data was analyzed with FlowJo, n=3/group.



**Supplementary Figure 2. Infiltration of immune cells into TC-1 tumor.** TC-1 tumor bearing female C57BL/6J mice were treated with PBS control (100  $\mu$ l s.c), R-DOTAP (100  $\mu$ l s.c), PDS0101 (s.c., 3 weekly doses starting on day 7), Bintrafusp alfa (250  $\mu$ g, i.p., days 7, 9, and 11), and/or NHS-IL-12 (50  $\mu$ g, s.c., day 7). **A:** Total NK in tumor. **B:** M1 macrophage infiltration per mg tumor. **C:** MDSC infiltration per mg tumor. **D:** Treg infiltration per mg tumor. MDSC, myeloid derived suppressor cells; NK, natural killer; Treg, regulatory T cells.